Onconova Therapeutics (NASDAQ:ONTX) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Onconova Therapeutics (NASDAQ:ONTX) in a note issued to investors on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Onconova Therapeutics Stock Performance

The company has a market cap of $20.90 million, a P/E ratio of -1.09 and a beta of 1.38. The firm’s fifty day moving average is $0.84 and its 200 day moving average is $0.74. Onconova Therapeutics has a 12-month low of $0.55 and a 12-month high of $1.45.

About Onconova Therapeutics

Onconova Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer.